Baird Maintains Outperform on Biogen, Raises Price Target to $290
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $250 to $290.
Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $250 to $290.